Cerus Corporation (CERS)vsDexCom Inc (DXCM)
CERS
Cerus Corporation
$2.89
+0.70%
HEALTHCARE · Cap: $575.06M
DXCM
DexCom Inc
$75.14
+0.39%
HEALTHCARE · Cap: $29.58B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 2125% more annual revenue ($4.82B vs $216.56M). DXCM leads profitability with a 19.3% profit margin vs -4.4%. DXCM earns a higher WallStSmart Score of 72/100 (B).
CERS
Avoid31
out of 100
Grade: F
DXCM
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CERS.
Margin of Safety
+89.6%
Fair Value
$656.95
Current Price
$75.14
$581.81 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 24.1% year-over-year
Every $100 of equity generates 31 in profit
Earnings expanding 92.2% YoY
Strong operational efficiency at 21.4%
15.0% revenue growth
Areas to Watch
Trading at 8.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 9.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CERS
The strongest argument for CERS centers on Revenue Growth. Revenue growth of 24.1% demonstrates continued momentum.
Bull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.
Bear Case : CERS
The primary concerns for CERS are Price/Book, EPS Growth, Market Cap.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Key Dynamics to Monitor
CERS profiles as a growth stock while DXCM is a mature play — different risk/reward profiles.
CERS carries more volatility with a beta of 1.77 — expect wider price swings.
CERS is growing revenue faster at 24.1% — sustainability is the question.
DXCM generates stronger free cash flow (449M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 31/100), backed by strong 19.3% margins and 15.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cerus Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.
Visit Website →DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?